

Dr. Zahed Subhan Biography

Dr. Zahed Subhan has over 25 years experience in the multinational pharmaceutical and biotechnology industries spanning senior roles in Research and Development, Marketing, Sales and Strategic Planning, including managerial positions with Sanofi-Aventis, GlaxoSmithKline, Merck & Co., the Dupont-Merck Pharmaceutical Company, Gemini Genomics Inc. and Locus Pharmaceuticals Inc. Key positions held by Dr. Subhan include, Director of Research, Head of Marketing and Sales, Vice President, Marketing and Business Development, and Chief Business Officer. Dr. Subhan was also previously CEO of Nuevolution A/S based in Copenhagen, Denmark and was a co-founder and CEO of Marillion Pharmaceuticals Inc. Dr. Subhan has also raised over \$40MM from venture capital firms to fund emerging biotechnology enterprises, and has been instrumental in establishing more than 40 collaborations and co-operative agreements with major pharmaceutical and biotech companies, including licensing, co-marketing and acquisition transactions valued in excess of \$600MM. Other career highlights include the successful launches of "blockbuster" drugs, including Imitrex®, Celexa®, Prinivil®/Zestril®, Sinemet CR® and Viazem®/Tiazac®, and the successful IPO of Gemini Genomics Inc. and its subsequent sale to Sequenom Inc.

Dr. Subhan holds a BSc (Honors) in Pharmacology from the University of Sunderland School of Pharmacy (UK), an MSc in Applied Industrial Psychology from the Aston University Business School (UK), a PhD in Experimental Psychology from the University of Leeds (UK), an MBA from the University of Bradford Management Centre (UK) and a JD/LLB (Law) degree from Thames Valley University, London. He has taught business students at both the undergraduate and graduate levels in courses including marketing, sales, entrepreneurship, business law and strategic management.

Dr. Subhan is a published researcher with particular interests in marketing strategy, innovation management and entrepreneurship and is an active consultant to the pharmaceutical and biotechnology industries.